-
Is the Practice of "Prioritizing Biologics over Small Molecule Drugs" Justified?
Krebs Qin
March 14, 2025
The article compares small molecule drugs and biologics in development, cost, etc., questions biologic - preferential policies, and mentions related acts for policy correction.
-
Inauguration of the New Richter BioLogics cGMP Facility for the Manufacture of Biopharmaceuticals for the Global Market
PharmaSources
October 14, 2024
Richter BioLogics GmbH & Co KG, the microbial biologics affiliate of Gedeon Richter Plc. celebrated the opening of its new cutting-edge biopharmaceutical cGMP facility in Bovenau .
-
Research Progress on the Application of Biologics in Pediatric Asthma
Xiaomichong
July 19, 2024
Asthma is a heterogeneous and complex chronic disease. Children with severe asthma often experience acute exacerbations, ultimately leading to impaired lung function and poor quality of life.
-
Celonic Inaugurates “Next Generation” Biologics Development Center (BDC) and Pilot Plant in Basel, Switzerland
Biotech Newswire
June 24, 2024
The Celonic Group, a Swiss Based Quality Biologics Contract Development and Manufacturing Organization (CDMO) today opened its “Next Generation” Biologics Development Center and Pilot Plant in Basel, Switzerland.
-
Research Progress on the Application of Biologics in Childhood Asthma.
Xiaomichong
October 30, 2023
Asthma is a heterogeneous, complex chronic disease. Children with severe asthma often experience acute exacerbations, leading to impaired lung function and poor quality of life.
-
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
PRNewswire
January 31, 2025
Telix completes the acquisition from ImaginAb, getting a drug pipeline and a biologics technology platform.
-
Samsung Biologics presents business updates at 2025 J.P. Morgan Healthcare Conference
PRNewswire
January 15, 2025
Samsung Biologics (KRX: 207940.KS) announced its latest business achievements and 2025 outlook at the 43rd J.P. Morgan Healthcare Conference, which was held in San Francisco between January 13-16.
-
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
PR Newswire
January 13, 2025
Telix Pharma acquires ImaginAb's therapeutic pipeline, tech platform & research facility for innovation boost
-
Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development
PRNewswire
January 09, 2025
Samsung Biologics (KRX: 207940.KS) announced to extend collaboration with LigaChem Biosciences (KOSDAQ: 141080) to provide antibody-drug conjugate (ADC) services.
-
Polpharma Biologics Announces Approval of Europe’s First and Only Biosimilar for Multiple Sclerosis - Tyruko® (Natalizumab)
B3C newswire
November 06, 2023
Polpharma Biologics, today announced that the European Commission (EC) has approved Tyruko® (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe.